Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Montelukast 10 mg vs Singulair 10 mg in healthy Thai volunteers under fasting
TCTR20210707005Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of montelukast in asthma and allergic rhinitis (AR) (2 arms), sponsored by Bio-innova. Primary endpoint: Primary bioequivalence endpoints. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
montelukast
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on TCTR20210707005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210707005.